Cardio Company Equity Multiplier from 2010 to 2025

CDIOW Stock  USD 0.09  0.01  6.67%   
Cardio Diagnostics Company Equity Multiplier yearly trend continues to be fairly stable with very little volatility. Company Equity Multiplier is likely to outpace its year average in 2025. During the period from 2010 to 2025, Cardio Diagnostics Company Equity Multiplier regression line of quarterly data had mean square error of  3.21 and geometric mean of  4.63. View All Fundamentals
 
Company Equity Multiplier  
First Reported
2010-12-31
Previous Quarter
1.73
Current Value
3.14
Quarterly Volatility
2.72324512
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cardio Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardio Diagnostics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 134.8 K or Selling General Administrative of 8.4 M, as well as many indicators such as Price To Sales Ratio of 2 K, Dividend Yield of 0.0 or PTB Ratio of 11.67. Cardio financial statements analysis is a perfect complement when working with Cardio Diagnostics Valuation or Volatility modules.
  
Check out the analysis of Cardio Diagnostics Correlation against competitors.

Latest Cardio Diagnostics' Company Equity Multiplier Growth Pattern

Below is the plot of the Company Equity Multiplier of Cardio Diagnostics Holdings over the last few years. It is Cardio Diagnostics' Company Equity Multiplier historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cardio Diagnostics' overall financial position and show how it may be relating to other accounts over time.
Company Equity Multiplier10 Years Trend
Slightly volatile
   Company Equity Multiplier   
       Timeline  

Cardio Company Equity Multiplier Regression Statistics

Arithmetic Mean5.64
Geometric Mean4.63
Coefficient Of Variation48.30
Mean Deviation2.42
Median7.39
Standard Deviation2.72
Sample Variance7.42
Range6.3629
R-Value(0.77)
Mean Square Error3.21
R-Squared0.60
Significance0.0005
Slope(0.44)
Total Sum of Squares111.24

Cardio Company Equity Multiplier History

2025 3.14
2024 1.73
2023 1.51
2022 1.45
2021 1.03

About Cardio Diagnostics Financial Statements

Cardio Diagnostics investors use historical fundamental indicators, such as Cardio Diagnostics' Company Equity Multiplier, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cardio Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Company Equity Multiplier 1.73  3.14 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cardio Stock Analysis

When running Cardio Diagnostics' price analysis, check to measure Cardio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardio Diagnostics is operating at the current time. Most of Cardio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Cardio Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardio Diagnostics' price. Additionally, you may evaluate how the addition of Cardio Diagnostics to your portfolios can decrease your overall portfolio volatility.